Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 16/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212938 | 0.91 | PTK2 (0.61) | PTK2PTK2BAURKABRD4 | |
| SCHEMBL5210760 | 0.91 | PTK2 (0.50) | PTK2PTK2BAURKACLK2AURKB | |
| SCHEMBL5214796 | 0.88 | PTK2 (0.46) | PTK2CDK1 | |
| SCHEMBL6240449 | 0.87 | CDK1 (0.43) | PTK2PTK2BCDK1 | |
| SCHEMBL5210356 | 0.87 | PTK2 (0.60) | PTK2PTK2B | |
| SCHEMBL6212509 | 0.86 | CDK1 (0.50) | PTK2PTK2BBRD4CDK1 | |
| SCHEMBL6211231 | 0.86 | CDK1 (0.43) | PTK2PTK2BCDK1 | |
| SCHEMBL6237252 | 0.86 | CDK1 (0.45) | PTK2PTK2BCDK1 | |
| SCHEMBL6243295 | 0.85 | KDM4E (0.45) | PTK2PTK2BBRD4CDK1 | |
| SCHEMBL6239285 | 0.85 | CDK1 (0.42) | PTK2PTK2BCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, CCNA1 | PTK2 3610/4885PTK2B 3168/4885AURKA 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.